研究单位：[1]Jiangsu HengRui Medicine Co., Ltd.[2]First Affiliated Hospital of University of Science and Technology of China,Hefei,Anhui,China,230002[3]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,Beijing,China,100021[4]Beijing Cancer Hospital,Beijing,Beijing,China,100142[5]Chongqing University Cancer Hospital,Chongqing,Chongqing,China,400000[6]The First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China,400016[7]Guangxi Medical University Affiliated Tumor Hospital,Nanning,Guangxi,China,530022[8]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050001[9]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150001[10]Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology,Wuhan,Hubei,China,430030[11]Hunan Cancer Hospital,Changsha,Hunan,China,410013[12]Liaoning Cancer Hospital,Shenyang,Liaoning,China,110042[13]Qilu Hospital of Shandong University,Jinan,Shandong,China,250000[14]Shandong First Medical University Affiliated Cancer Hospital,Jinan,Shangdong,China,250117[15]Shanxi Provincial Cancer Hospital,Taiyuan,Shanxi,China,030006[16]Sichuan Cancer Hospital,Chengdu,Sichuan,China,610042[17]Tianjin Cancer Hospital,Tianjin,Tianjin,China,300000[18]Yunnan Cancer Hospital,Kunming,Yunnan,China,650118[19]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310005
研究目的：
This study is a multicenter, open-label Phase Ib/II clinical trial to observe and evaluate the safety, tolerability and pharmacokinetics of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer mechanical characterization and preliminary evaluation of the efficacy of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer.
